Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- NXTC
- Price
- 12.65
- Stock movement down
- -0.34 (-2.62%)
- Company name
- NextCure Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 44.35M
- Ent value
- 52.99M
- Price/Sales
- 13.51
- Price/Book
- 1.88
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -63.55%
- 1 year return (CAGR)
- -99.09%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
NXTC does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 13.51 |
| Price to Book | 1.88 |
| EV to Sales | 16.15 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 3.51M |
| EPS (TTM) | -21.68 |
| FCF per share (TTM) | -18.30 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 3.28M |
| Gross profit (TTM) | 354.00K |
| Operating income (TTM) | -60.31M |
| Net income (TTM) | -58.01M |
| EPS (TTM) | -21.68 |
| EPS (1y forward) | -8.22 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 10.79% |
| Operating margin (TTM) | -1837.72% |
| Profit margin (TTM) | -1767.55% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 7.32M |
| Net receivables | 0.00 |
| Total current assets | 32.64M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 6.42M |
| Total assets | 39.61M |
| Accounts payable | 2.39M |
| Short/Current long term debt | 4.41M |
| Total current liabilities | 10.99M |
| Total liabilities | 15.97M |
| Shareholder's equity | 23.65M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -48.94M |
| Capital expenditures (TTM) | 34.00K |
| Free cash flow (TTM) | -48.98M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -245.33% |
| Return on Assets | -146.44% |
| Return on Invested Capital | -245.33% |
| Cash Return on Invested Capital | -207.13% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 12.70 |
| Daily high | 12.90 |
| Daily low | 12.06 |
| Daily Volume | 28K |
| All-time high | 159356.16 |
| 1y analyst estimate | 17.67 |
| Beta | 1.54 |
| EPS (TTM) | -21.68 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| NXTC | S&P500 | |
| Current price drop from All-time high | -99.99% | -0.89% |
| Highest price drop | -100.00% | -19.00% |
| Date of highest drop | 5 Sep 2025 | 8 Apr 2025 |
| Avg drop from high | -99.52% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
44.35M
Marketcap category
Small-cap
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Employees
43
Website
Investor relations
-
SEC filings
CEO
Michael S. Richman
Country
USA
City
Beltsville
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page